Olema Pharmaceuticals, Inc. is not hurting for money after raising $139m in venture capital so far in 2020, but the company went public in the US on 18 November anyway to speed up clinical development of lead drug candidate OPI-1250, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) undergoing a Phase I/II clinical trial in patients with estrogen receptor-positive (ER+)/HER2-negative locally advanced or metastatic breast cancer.
San Francisco-based Olema, also known as Olema Oncology, brought in $209m from the sale of 11 million shares at $19...